Search Results
147 results found-
With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology -
CSL is committed to pricing practices that reflect the value our products bring to patients and society.
https://www.csl.com/sustainability/healthier-communities/access-and-affordability -
CSL's is recognized for our contributions to developing breakthrough medicines that have the potential to help millions of patients worldwide.
https://www.csl.com/research-and-development/r-and-d-capabilities -
With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus offers a broad portfolio of innovative, differentiated vaccines in more than 20 countries around the world.
https://newsroom.csl.com/2025-04-29-CSL-Seqirus,-a-Global-Leader-in-Pandemic-Preparedness-and-Outbreak-Response,-Signs-an-Agreement-with-the-European-Commission-to-Support-Pandemic-Preparedness-Plans -
With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics -
With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
https://newsroom.csl.com/2023-09-18-CSL-Seqirus-Shares-Data-Demonstrating-the-Potential-for-Influenza-Vaccination-to-Reduce-the-Burden-on-Healthcare-Resources -
CSL conducts clinical trials on all of its products. See if one of our current clinical trials might be right for you.
https://www.csl.com/research-and-development/clinical-studies/current-clinical-trials -
This capacity ensuresconsists that of approximately 13,000 square metres overall with CSL PlasmaWith testing is one now of the based largest in Holly Springs, CSL Seqirus has been CSL's state-of-the art R&D centre in CSL Seqirus is able to support5,000 US square health metres of laboratory space - including the first plasmaable collection to simplify networks and streamline in the the testing process to release Waltham, Massachusetts, continues to authorities on pandemic preparedness.biosafety level 3 laboratory (BSL-3) in Waltham - and the ability worldFLUCELVAX and is headquartered® influenza vaccine in Boca into the US each season.
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2023-24.pdf -
Commune et code Numéro Pays du postal du cabinet principal Adresse (rue/numéro/bte) du cabinet unique Contribution aux frais relatifs à des manifestations scientifiques Honoraires pour services et consultance (Art.
https://www.csl.com/-/media/shared/documents/vifor-disclosures/disclosure-reports/csl-vifor_luxembourg-efpia_fr_06062024.pdf -
strategic global partnering, in-licensing innovative therapies for people living CSL Seqirus operates state-of-the-art and developing, manufacturing and with conditions in the immunology, production facilities in the US, the UK marketing pharmaceutical products haematology, cardiovascular and and Australia and uses both egg-based for precision healthcare, aiming to metabolic, respiratory, and transplant and cell-based manufacturing help patients around the world lead therapeutic areas.
https://www.csl.com/-/media/csl/documents/csl-statement-on-modern-slavery-2024.pdf